HUM vs MNPR · P/E 39, rev $117.76B vs $431.4M cap
Humana Inc (HUM) versus Monopar Therapeutics Inc (MNPR) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Monopar Therapeutics Inc (MNPR) is a biotechnology company listed on US.
Latest reported HUM revenue for 2024-12-31 was $117.76B. Net income was $1.21B. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported MNPR revenue for 2024-12-31 was $0. Net income was -$15.6M. MNPR currently screens at market cap $431.4M.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. MNPR currently screens at market cap $431.4M.
Not investment advice. Open the HUM and MNPR stock pages for the full models.
Not investment advice.